{"id":"comparator-micafungin-sodium","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Phlebitis at infusion site"},{"rate":"10-20","effect":"Elevated liver enzymes (AST/ALT)"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Rash"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Micafungin is an echinocandin antifungal that selectively inhibits the enzyme 1,3-beta-D-glucan synthase in the fungal cell wall. This prevents the synthesis of beta-glucan, a critical structural component of the fungal cell wall, causing cell wall integrity to fail and resulting in fungal cell lysis and death. It has broad-spectrum activity against Candida and Aspergillus species.","oneSentence":"Micafungin sodium inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase, leading to fungal cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:00.104Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Candidemia and acute disseminated candidiasis"},{"name":"Esophageal candidiasis"},{"name":"Prophylaxis of Candida infections in hematopoietic stem cell transplant recipients"},{"name":"Aspergillus infections (invasive aspergillosis)"}]},"trialDetails":[{"nctId":"NCT00717860","phase":"PHASE3","title":"A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Fungal Infection","enrollment":121},{"nctId":"NCT01344681","phase":"PHASE2","title":"Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-06","conditions":"Febrile Neutropenia, Hematological Diseases","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: Micafungin sodium","genericName":"Comparator: Micafungin sodium","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Micafungin sodium is a comparator used in clinical studies for treating fungal infections, febrile neutropenia, and hematological diseases. It is compared to caspofungin acetate in these studies, suggesting that micafungin sodium is used as a reference treatment for these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}